Baoqing Chen, Zimeng Li, Xingyuan Cheng, Mian Xi. "Reply to: “Tislelizumab With Chemoradiotherapy in Esophageal Squamous Cell Carcinoma: Questions on Treatment Tolerance and Follow-Up Duration” and “NRF2 Pathway Status and Maintenance Immunotherapy Exposure in EC-CRT-002”." Journal of Clinical Oncology, 2026. doi:10.1200/jco-26-01677